Article
A multiprotein supercomplex controlling oncogenic signalling in lymphoma.
Nature - 1 Aug 2018
Phelan James D, Young Ryan M, Webster Daniel E, Roulland Sandrine, Wright George W, Kasbekar Monica, Shaffer Arthur L, Ceribelli Michele, Wang James Q, Schmitz Roland, Nakagawa Masao, Bachy Emmanuel, Huang Da Wei, Ji Yanlong, Chen Lu, Yang Yandan, Zhao Hong, Yu Xin, Xu Weihong, Palisoc Maryknoll M, Valadez Racquel R, Davies-Hill Theresa, Wilson Wyndham H, Chan Wing C, Jaffe Elaine S, Gascoyne Randy D, Campo Elias, Rosenwald Andreas, Ott German, Delabie Jan, Rimsza Lisa M, Rodriguez Fausto J, Estephan Fayez, Holdhoff Matthias, Kruhlak Michael J, Hewitt Stephen M, Thomas Craig J, Pittaluga Stefania, Oellerich Thomas, Staudt Louis M
Abstract excerpt
B cell receptor (BCR) signalling has emerged as a therapeutic target in B cell lymphomas, but inhibiting this pathway in diffuse large B cell lymphoma (DLBCL) has benefited only a subset of patients1. Gene expression profiling identified two major subtypes of DLBCL, known as germinal centre B cell-like and activated B cell-like (ABC)2,3, that show poor outcomes after immunochemotherapy in ABC. Autoantigens drive...
Topics
Join the communities discussing this publication.